Human Receptor for advanced glycation end products, RAGE/AGER ELISA Kit

Instructions
Code CSB-E09354h
Size 96T
Trial Size 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name advanced glycosylation end product-specific receptor
Alternative Names Advanced glycosylation end product-specific receptor ELISA Kit; Ager ELISA Kit; DAMA 358M23.4 ELISA Kit; MGC2235 ELISA Kit; MGC22357 ELISA Kit; RAGE_HUMAN ELISA Kit; Receptor for advanced glycation end products ELISA Kit; Receptor for advanced glycosylation end products ELISA Kit
Abbreviation AGER
Uniprot No. Q15109
Species Homo sapiens (Human)
Sample Types serum, plasma, tissue homogenates
Detection Range 78 pg/mL-5000 pg/mL
Sensitivity 19.5 pg/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Immunology
Precision
Intra-assay Precision (Precision within an assay): CV%<8%      
Three samples of known concentration were tested twenty times on one plate to assess.  
Inter-assay Precision (Precision between assays): CV%<10%      
Three samples of known concentration were tested in twenty assays to assess.    
             
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human AGER in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)  
1:1 Average % 88  
Range % 80-93  
1:2 Average % 92  
Range % 88-96  
1:4 Average % 89  
Range % 85-96  
1:8 Average % 93  
Range % 90-97  
Recovery
The recovery of human AGER spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range  
Serum (n=5) 92 87-96  
EDTA plasma (n=4) 95 91-99  
             
             
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
pg/ml OD1 OD2 Average Corrected  
5000 2.702 2.719 2.711 2.512  
2500 2.011 2.062 2.037 1.838  
1250 1.403 1.421 1.412 1.213  
625 0.928 0.939 0.934 0.735  
312 0.571 0.581 0.576 0.377  
156 0.386 0.396 0.391 0.192  
78 0.275 0.262 0.269 0.070  
0 0.197 0.200 0.199    
Troubleshooting
and FAQs
ELISA kit FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 3-5 working days

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Earn $30 Amazon Card or 20μL/μg CUSABIO Trial Size Antibody. Details of rewards >>

Target Background

Function
(From Uniprot)
Mediates interactions of advanced glycosylation end products (AGE). These are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. Acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes. AGE/RAGE signaling plays an important role in regulating the production/expression of TNF-alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes. Interaction with S100A12 on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation, with generation of key proinflammatory mediators. Interaction with S100B after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53/TP53 signaling (By similarity). Receptor for amyloid beta peptide. Contributes to the translocation of amyloid-beta peptide (ABPP) across the cell membrane from the extracellular to the intracellular space in cortical neurons. ABPP-initiated RAGE signaling, especially stimulation of p38 mitogen-activated protein kinase (MAPK), has the capacity to drive a transport system delivering ABPP as a complex with RAGE to the intraneuronal space. Can also bind oligonucleotides.
Gene References into Functions
  1. In a candidate association study identified 2 polymorphisms (T-429C and G1704T) in RAGE, which were not only associated with increased MI risk but also interacted with metabolic risk factors to increase that risk. PMID: 28956473
  2. High RAGE expression is associated with Breast Carcinoma. PMID: 30139236
  3. AGEs increase IL-6 and ICAM-1 expression via the RAGE, MAPK and NF-kappaB pathways in HGFs and may exacerbate the progression of the pathogenesis of periodontal diseases. PMID: 29193068
  4. Low serum sRAGE level is associated with Sarcopenia. PMID: 29271076
  5. Results show that RAGE is activated by HMGB1 to induce EMT in prostate cancer cells. PMID: 29845254
  6. Endogenous secretory receptor for advanced glycation end products protects endothelial cells from advanced glycosylation end-product associated apoptosis. PMID: 29850572
  7. high mobility group box 1-receptor for advanced glycation end-products (HMGB1-RAGE) signaling pathway may be involved in the pathogenesis of preterm premature rupture of the membranes (pPROM). PMID: 29673663
  8. Results show that RAGE is upregulated in breast cancer tissues, and confirmed that RAGE was a direct target of miR-328. PMID: 29620238
  9. The results suggest that S100A12 does not participate in the induction of inflammation in dental pulp. However, RAGE can participate in the inflammation in the pulp of males. PMID: 28834384
  10. The results show for the first time that RAGE is present in neuronally-derived plasma exosomes, and suggest that exosomal RAGE may be a novel biomarker that reflects pathophysiological processes in the brain. PMID: 29702093
  11. Decreased soluble RAGE in neutrophilic asthma is correlated with disease severity and RAGE G82S variants. PMID: 29257350
  12. Our study provides novel evidence for a potential role of AGER in bridging human papillomavirus (HPV)-induced inflammation and cervical cancer. PMID: 29298878
  13. Plasmatic RAGE level is significantly lower in patients with prosthetic-joint-associated infections. PMID: 29386700
  14. Inhibition of GLO1 in Glioblastoma Multiforme Increases DNA-AGEs, Stimulates RAGE Expression, and Inhibits Brain Tumor Growth in Orthotopic Mouse Models PMID: 29385725
  15. a significant association between RAGE gene rs1800624 and rs1800625 polymorphisms and Age-related macular degeneration risk, is reported. PMID: 29317590
  16. HMGB1 mediates fibroblast activity via RAGE-MAPK and NF-kappaB signaling in keloid scar formation. PMID: 29283384
  17. Data revealed that hESC accumulates CML and RAGE under oxidative stress conditions in different ways than somatic cells, being the accumulation of CML statistically significant only in somatic cells and, conversely, the RAGE increase exclusively appreciated in hESC. PMID: 29104727
  18. In women with Polycystic ovary syndrome(PCOS), the low ovarian levels of the anti-inflammatory sRAGE suggest that sRAGE could represent a biomarker and a potential therapeutic target for ovarian dysfunction in PCOS. Whether there is a direct causal relationship between sRAGE and vit D in the ovaries remains to be determined PMID: 28825156
  19. current research highlighted the Glo-I/AGE/RAGE system as an interesting therapeutic target in chronic liver diseases. These findings need further elucidation in preclinical and clinical studies. PMID: 29156655
  20. Low esRAGE expression is associated with bone Fractures. PMID: 29040721
  21. Elevated sRAGE serum level is associated with further adverse events in patients with cardiovascular disease. PMID: 28864204
  22. Our findings suggested that polymorphisms in the RAGE gene are involved in genetic susceptibility to Alzheimer disease but did not modify the risk of lewy body disease. PMID: 27699858
  23. Findings suggest soluble Receptor for Advanced Glycation End products (sRAGE) protein from sRAGE-mesenchymal stem cells (MSC) has better protection against neuronal cell death than sRAGE protein or single MSC treatment by inhibiting the RAGE cell death cascade and RAGE-induce inflammation. PMID: 28760504
  24. Protection against diabetic nephropathy in RAGE knockout mice is likely to be due in part to the decreased responsiveness to TGF beta stimulation and an antiapoptotic phenotype in mesangial cells. PMID: 29449307
  25. the A allele of RAGE -374T/A polymorphism probably increase diabetic retinopathy risk (Meta-Analysis) PMID: 29451661
  26. Advanced glycation end products decrease collagen I levels in fibroblasts from the vaginal wall of patients with pelvic organ prolapse via the RAGE, MAPK and NF-kappaB pathways. PMID: 28849117
  27. we identified two risk-associated polymorphisms (rs1045411 and rs2070600), and more importantly a joint impact of seven polymorphisms from the HMGB1/RAGE axis in susceptibility to hepatocellular carcinoma PMID: 28187002
  28. type 2 diabetes showed a higher cellular sensitivity for activation of receptor of advanced glycation end products. PMID: 27873077
  29. the G82S variant of the RAGE gene was significantly associated with an increased risk of all-cause mortality and acute myocardial infarction in the Chinese Han population. PMID: 28660308
  30. both RAGE and mitochondrial damage primed NLRP3 and pro-IL-1beta activation as upstream signals of NF-kappaB activity, whereas mitochondrial damage was critical for the assembly of inflammasome components. These results revealed that accumulation of AGEs in NP tissue may initiate inflammation-related degeneration of the intervertebral disc via activation of the NLRP3 inflammasome. PMID: 28224704
  31. The main mechanism of Integrin alphaXbeta2 I-domain binding to RAGE is a charge interaction, in which the acidic moieties of Integrin alphaXbeta2 I-domains, including E244, and D249, recognize the basic residues on the RAGE V-domain encompassing K39, K43, K44, R104, and K107. PMID: 28535664
  32. An overexpression of the receptor for RAGE was found in lesioned samples of patients with acquired reactive perforating collagenosis. PMID: 28474638
  33. Single-nucleotide polymorphism in RAGE gene and high circulating soluble RAGE level is associated with diabetic kidney disease. PMID: 27448675
  34. Significant association of the RAGE system with Hashimoto's thyroiditis was found only with regard to the prevalence of the -429T>C, but not with -374T>A polymorphism. PMID: 28226412
  35. study revealed an early and constant increase of sRAGE level in the CSF of aneurysmal subarachnoid haemorrhage patients. PMID: 28630869
  36. These data indicate that sRAGE may be involved in the initiation of beta-cell autoimmunity but not in the progression from beta-cell autoimmunity to clinical disease. PMID: 27883367
  37. IL-23, alone and in combination with IL-18 and sRAGE, identified bacterial meningitis with excellent accuracy. Following validation, these markers could aid clinicians in diagnosis of bacterial meningitis and decision-making regarding prolongation of antibiotic therapy PMID: 29394248
  38. meta-analysis aimed at investigating whether the RAGE rs2070600 polymorphism is associated with cancer risk PMID: 29421442
  39. found that S100B plays a crucial role in blocking the interaction site between RAGE V domain and S100A1. A cell proliferation assay WST-1 also supported our results. This report could potentially be useful for new protein development for cancer treatment PMID: 29444082
  40. Lower plasma sRAGE levels may be a biological measure of disease severity in idiopathic pulmonary fibrosis (IPF). Variation at the rs2070600 single-nucleotide polymorphism was not associated with IPF risk. PMID: 28248552
  41. Results suggest a possible association between a functional polymorphism in AGER and IPF disease susceptibility, and indicate a potential prognostic value of circulatory sRAGE. PMID: 28198072
  42. Thus, hypoxia not only increases RAGE expression in THP-1cells by promoting nuclear translocation of NF-kappa B and HIF1alpha, but also regulates chemotaxis and pro-inflammatory cytokines release, which may be partially mediated through upregulation of RAGE expression. PMID: 29258824
  43. This study demonstrated that RAGE mRNA levels were significantly decreased in the new cases of untreated MS patients in comparison to healthy controls. IFN-beta 1a therapy results in upregulation of RAGE in MS patients. PMID: 28433998
  44. High RAGE expression is associated with lung cancer. PMID: 26930711
  45. findings collectively demonstrate that fasting blood sRAGE and esRAGE may be causally implicated in IGM in primary hypertensive patients PMID: 28974473
  46. Our data suggest that the inhibition of sRAGE on I/R-induced apoptosis is associated with activation and expression of proteasome, including improved proteasome activity and elevated beta1i and beta5i expression mediated by STAT3 activation. We predict that sRAGE is a novel intervention to target UPS activation for preventing and treating myocardial apoptosis. PMID: 26878774
  47. Receptor for AGE expression and reactive oxygen species production were upregulated in db/db mouse livers, together with impaired proteolytic, antioxidant and mitochondrial respiratory activities. In parallel, acute exposure of HepG2 cells to glycated albumin also elicited intracellular free radical formation PMID: 27890722
  48. Our data suggest that H2S reduces RAGE dimer formation and impairs its membrane stability. The lowered plasma membrane abundance of RAGE therefore helps to protect cells against various RAGE mediated pathological effects. PMID: 28108276
  49. Methylglyoxal-derived hydroimidazolone 1 evokes inflammatory reactions in human umbilical vein endothelial cells via receptor for advanced glycation end products. PMID: 28631505
  50. Reduced values of sRAGE isoforms observed with both obesity and impaired glucose tolerance are independently associated with greater proportional odds of developing type 2 diabetes PMID: 28811295

Show More

Hide All

Subcellular Location Isoform 1: Cell membrane, Single-pass type I membrane protein, SUBCELLULAR LOCATION: Isoform 2: Secreted, SUBCELLULAR LOCATION: Isoform 10: Cell membrane, Single-pass type I membrane protein
Tissue Specificity Endothelial cells.
Database Links

HGNC: 320

OMIM: 600214

KEGG: hsa:177

STRING: 9606.ENSP00000364217

UniGene: Hs.534342

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2021 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1